ProCE Banner Activity

HPTN 083: Safety, Efficacy, and Gender-Affirming Hormonal Therapy Interactions With Long-Acting Injectable CAB for HIV PrEP in Transgender Women

Slideset Download
Conference Coverage
Gender-affirming hormonal therapy did not appear to affect cabotegravir concentrations in transgender women in this preliminary analysis from HPTN 083.

Released: August 01, 2022

Expiration: July 31, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner